Lawsuit challenges Cipla's buyout of InvaGen

India's Cipla announced a $550 million deal last month to buy New York-based InvaGen and a related company in its first foray into manufacturing in the U.S. But a hitch in the deal has developed as New Jersey-based PuraCap Pharmaceutical has filed suit claiming InvaGen breached unspecified obligations to it but "improperly negotiating" with Cipla, the Economic Times reports. Story | More

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.